Roche Holding (0TDF) AI Stock Analysis

0 Followers

Roche Holding

(LSE:0TDF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

High profitability and cash generationRoche combines high gross and operating margins with consistently positive free cash flow, indicating a strong economic model and meaningful internal funding capacity. This supports continued investment in research, launches and commercial infrastructure while providing resilience across the next several quarters.

Negative Factors

Meaningful leverageAlthough leverage improved, Roche’s financing mix still provides less balance-sheet cushion than more conservatively funded peers. Higher debt relative to equity can constrain flexibility for acquisitions, shareholder distributions and research investment if earnings or cash generation weaken.

Roche Holding (0TDF) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $387.10B
Dividend Yield: 2.58%
Average Volume (3M): 13.29K
Price to Earnings (P/E): 26.3
Beta (1Y): 0.98
Revenue Growth: 8.13%
EPS Growth: 42.71%
Country: UK
Employees: 103,249
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Roche Holding Business Overview & Revenue Model

Company Description

Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries...

Roche Holding Earnings Call Summary

Earnings Call Date:Jul 23, 2026(Q2-2026)|% Change Since:19.19%|Next Earnings Date:Jan 28, 2027

Earnings Call SentimentPositive

Overall the call conveyed a positive operating and pipeline momentum despite identifiable headwinds. Roche reported strong profitability (core op profit +10%, margin expansion), solid organic growth in Pharma, multiple regulatory wins (5 priority reviews) and major diagnostics and R&D milestones (AXELIOS launch, CE marks, strategic M&A). Offsetting items include China pricing reform and a weak respiratory season hitting Diagnostics, currency translation pressures, a near‑term net debt increase (timing effects) and some competitive/biosimilar pressure in specific franchises. On balance, the operational and pipeline achievements materially outweigh the manageable challenges described.

Positive Updates

Strong profitability and margin expansion

Core operating profit up 10% (constant exchange rates) with core operating margin +1.7 percentage points; core EPS +9% (CER). Operating free cash flow +21% and free cash flow +58% (timing effects), demonstrating strong cash generation and margin discipline.

Negative Updates

China pricing reform significantly weighing on Diagnostics

China sales in Diagnostics declined ~15% (APAC -5% overall), with health‑care pricing reform materially reducing reported Diagnostics growth; excluding China effect Diagnostics would have grown +6%.

Company Guidance

Roche confirmed its 2026 guidance: mid‑single‑digit group sales growth (sales are running ~6% YTD) and high‑single‑digit core EPS growth (core EPS up ~9% H1), while reporting core operating profit up 10% YTD and a 1.7 percentage‑point improvement in core operating margin; management reiterated an expected LOE impact of ~CHF 600m for 2026, aims to keep Diagnostics’ margin broadly stable versus 2025 (14.4% CER) with Diagnostics growth targeted at mid‑single‑digits in 2026 (and mid‑ to high‑single‑digits in 2027), expects the core tax rate to normalize toward ~20% for the full year, flagged currency headwinds of roughly -4 p.p. on sales and -6 p.p. on core operating profit/core EPS for the year, said other revenue should rise from ~3% to ~5% of sales by the end of the decade, and confirmed a further increase in the dividend in Swiss francs.

Roche Holding Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0TDF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVS	72Outperform	$292.94B	30.72	24.24%	2.95%	1.64%	-28.72%
ABBV	71Outperform	$520.47B	50.60	-202.43%	2.35%	10.68%	338.08%
JNJ	70Outperform	$682.52B	43.32	19.55%	1.85%	7.81%	-35.95%
PFE	66Neutral	$164.33B	40.87	4.60%	5.95%	1.34%	-58.96%
MRK	64Neutral	$362.27B	149.25	5.29%	2.30%	5.21%	-86.88%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GB:0TDF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0TDF	Roche Holding AG	60.87	16.61	37.53%
JNJ	Johnson & Johnson	285.75	90.57	46.40%
MRK	Merck & Company	147.76	57.55	63.79%
NVS	Novartis AG	160.50	31.48	24.40%
PFE	Pfizer Inc	28.89	5.39	22.91%
ABBV	Abbvie	295.03	67.83	29.85%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Roche Holding AI Stock Analysis